Canaccord analyst John Newman initiated coverage of BridgeBio Oncology (BBOT) with a Buy rating and $23 price target
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBOT:
- Analyst Reiterates Buy on BridgeBio Oncology Therapeutics with Unchanged $29 12-Month Price Target Amid Promising Pan-KRAS Pipeline
- BridgeBio Oncology Overhauls Leadership for Next Development Phase
- BridgeBio Oncology appoints Pedro Beltran as CEO, Idan Elmelech as COO
- BridgeBio Oncology announces FDA Fast Track Designation for BBO-11818
- 3 Best Stocks to Buy Today, According to Top Analysts